𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low prevalence of antibody to hepatitis C virus in North East England

✍ Scribed by A. M. Brind; A. A. Codd; B. J. Cohen; F. G. Gabriel; J. D. Collins; O. F. W. James; Dr. M. F. Bassendine


Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
635 KB
Volume
32
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The prevalence of antibodies to hepatitis C virus (anti‐HCV) was studied in North East England in blood donors, local multiply transfused patients, local high risk individuals, and chronic liver disease patients. Anti‐HCV was detected by enzyme‐linked immunosorbent assay (ELISA) in 2/1120 (0.18%) blood donors; 1/84 chronic renal failure patients on haemodialysis who had received 1,992 units of blood (seroconversion rate of 0.05% per unit transfused), 1/207 cardiac patients 6 months post cardiac surgery transfused with 1,403 units of blood (1 anti‐HCV pre‐operatively, seroconversion rate 0.07%), 40/50 haemophilia A patients treated with commercial factor VIII, and 38/100 intravenous drug users. In addition anti‐HCV was detected by ELISA in 5/35 cryptogenic chronic liver disease patients, 5/5 confirmed by recombinant immunoblot assay (RIBA) (14%); 3/30 patients with autoimmune chronic active hepatitis, 2/3 by RIBA (7%); 2/50 primary biliary cirrhosis patients, 1/2 by RIBA (2%); 0/30 alcoholic cirrhosis patients; and 2/9 patients with hepatocellular carcinoma, 1/2 by RIBA (11%). HCV is uncommon in North East England; it may be implicated in the aetiology of a minority of cases of cryptogenic liver disease and <5% of autoimmune chronic active hepatitis and primary biliary cirrhosis.


📜 SIMILAR VOLUMES


Prevalence of hepatitis C virus antibodi
✍ Dr. M. Rapicetta; A. F. Attili; A. Mele; A. de Santis; P. Chionne; K. Cristiano; 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 554 KB

## Abstract Several studies had been carried out on anti‐hepatitis C virus (HCV) prevalence in populations with blood exposure risks and in blood donors. New tests are now available which allow the in‐ vestigation to extend to other parameters such as antibody type and HCV‐RNA. In this study the p

Low prevalence of hepatitis C virus anti
✍ Xing Li; Norio Hayashi; Nobukazu Yuki; Kazuhiro Katayama; Akinori Kasahara; Hide 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB 👁 1 views

## Abstract To evaluate the prevalence of hepatitis C virus infection in northwest China, 179 chronic liver disease patients in this area were examined for antibody to hepatitis C virus core protein (anti‐HCVcore). This antibody was found in only 5 (14 percent) of 37 chronic non‐A, non‐B liver dise

Prevalence of antibodies to hepatitis C
✍ Lennox J. Jeffers; Fuad Hasan; Maria de Medina; Rajender Reddy; Talley Parker; M 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB 👁 2 views

Many cases of chronic hepatitis and cirrhosis cannot be attributed to a known cause and are collectively referred to as cryptogenic chronic liver disease. We have evaluated the role of the hepatitis C virus in the pathogenesis of this condition in a retrospective serum analysis for antibody to hepat

Prevalence and significance of antibodie
✍ Professor E. A. Ayoola; S. Huraib; M. Arif; F. Z. Al-Faleh; R. Al-Rashed; S. Ram 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB 👁 2 views

## Abstract Seventy‐four patients who were maintained on chronic haemodialysis in King Khalid University Hospital, Riyadh, Saudi Arabia were tested using the recently available ELISA to determine the prevalence of antibodies to hepatitis C virus (anti‐HCV) in a haemodialysis unit. The prevalence r

Low prevalence of hepatitis C virus infe
✍ Mark Yen-Ping Kuo; Liang-Jiunn Hahn; Chi-Yuan Hong; Jia-Horng Kao; Dr. Ding-Shin 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB 👁 2 views

## Abstract To evaluate whether hepatitis C virus (HCV) infection is an occupational hazard in the dental environment, serum samples collected in 1990–1991 from 461 dentists were tested for the antibody to HCV (anti‐HCV) with first‐ and second‐generation HCV enzyme‐linked immunoassays (EIAs). Five